Peptide Therapeutics Market Is Projected To Grow Rapidly Due To Rising Incidences Of Metabolic Disorder Till 2025: Grand View Research, Inc.

The global peptide therapeutics market is expected to reach USD 48.04 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for efficient & rapid-acting therapeutics for treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, are anticipated to propel market growth. 

Rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives. Moreover, growing base of geriatric population is expected to widen the consumer base by triggering incidence rate of target diseases such as cancer & diabetes, which are expected to drive the demand for peptide therapeutics.
U.S. peptide therapeutics market, by drug type, 2014 - 2025 (USD Million)

Technological advancements in peptide manufacturing process is one of the major factors driving the market growth during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification & automation process and less generation of waste is an additional factor attributing toward market growth

Browse full research report on Peptide Therapeutics Market: www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market                                                             

 Further key findings from the report suggest:

  • Cancer held the largest market share in 2016 owing to increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment.
  • The generic drug segment is expected to showcase upward shift due to patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of generic class
  • Outsourced manufacturing is expected to grow at CAGR of 6.7% owing to requirements of complex procedures and shift in preference toward outsourcing, which helps in eliminating cost of production.
  • Route of administration including nasal and intradermal routes is expected to grow at a rapid pace owing to ease of usage and advantages over other routes of administration such as oral.
  • Hybrid technology is expected to spearhead the growth of this market. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth.
  • North America held the largest share in terms of revenue in 2016 owing to higher level of awareness pertaining to genomics & proteomics products, well-established R&D infrastructure, and rising funding initiatives
  • Asia Pacific industry is expected to showcase lucrative growth over the forecast period with CAGR of 11.0%. Presence of established generic industry and API providers in this region coupled with growing economic stability in some of the countries is expected to propel market growth.
  • Some of the key players in the peptide therapeutics market include Eli Lilly and Company; Pfizer, Inc.; Amgen, Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals Industries Ltd.; Lonza Inc.; Sanofi; Bristol-Myers Squibb (BMS); AstraZeneca PLC; GlaxoSmithKline plc (GSK); Novartis AG; and Novo Nordisk A/S
Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals                                                          

 Grand View Research has segmented the peptide therapeutics market by application, type, type of manufacturers, route of administration, synthesis technology, and region:

Peptide Therapeutics, Application Outlook (Revenue, USD Million; 2014 - 2025)
  • Cancers
  • Metabolic
  • Cardiovascular Disorder
  • Respiratory
  • GIT
  • Antiinfection
  • Pain
  • Dermatology
  • CNS
  • Renal
  • Others
Peptide Therapeutics, Type Outlook (Revenue, USD Million; 2014 - 2025)
  • Generic
  • Innovative
Peptide Therapeutics, Type of Manufacturers Outlook (Revenue, USD Million; 2014 - 2025)
  • In-house
  • Outsourced
Peptide Therapeutics, Route of Administration Outlook (Revenue, USD Million; 2014 - 2025)
  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others
Peptide Therapeutics, Synthesis Technology Outlook (Revenue, USD Million; 2014 - 2025)
  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology
Peptide Therapeutics, Regional Outlook (Revenue, USD Million; 2014 - 2025)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Mexico
    • Brazil
  • MEA
    • South Africa

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-peptide-therapeutics-market    
       
About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


For more information: www.grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Epigenetics Market to Observe Strong Development by 2022

The global  epigenetics market  is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.  Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is expected to attract pharmaceutical companies to collaborate for the development of therapeutic drugs.  Presence of pipeline drugs and their expected commercialization is anticipated to boost penetration rates over the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.  Technology advancements in the field of epigenetics especially pertaining to t
Read more

Increasing Incidences Of M&A Of CDMO/CRO With Big Pharma Companies To Drive Life Sciences BPO Market Growth Till 2024: Grand View Research, Inc.

Image
The  life sciences BPO market  is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.  The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.  North America life sciences BPO market, by services, 2013 - 2024 (USD Billion) In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth
Read more

U.S. Telehealth Market Is To Be $2.83 Billion By 2022: Grand View Research, Inc.

Image
U.S. telehealth market  is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research Inc. Increasing access to basic healthcare is the major aim of telehealth along with improved healthcare quality and patient safety by early detection and diagnosis. According to a report published by the Agency for Health Care Research and Quality (AHRQ), implementation of telehealth solution improves quality of care delivery to patients.  The rising demand for self care and independent living along with the concept of home care is highly appealing to the population. The Rhode Island Partnership for Home Care reported that in 2014, over 20,000 citizens demanded for home care that led to approximately 1,000,000 visits by healthcare providers. Advantages that drive the higher adoption for home care include better psychological impact on patients, provision of friendly environment, care provision as per patient needs, and cost-effectiveness.  U.S. telehealth
Read more